Garcia Denise D, Farjo Qais, Musch David C, Sugar Alan
Henry Ford Health System, Livonia, MI, USA.
Cornea. 2007 Sep;26(8):930-4. doi: 10.1097/ICO.0b013e3180e79b77.
To determine the effect of routine use of prophylactic oral acyclovir after penetrating keratoplasty (PK) for herpes simplex virus (HSV) keratitis on recurrence, rejection, and graft failure rates.
Records from 70 consecutive patients who underwent PK for HSV keratitis at the W.K. Kellogg Eye Center between August 1, 1990, and December 31, 2000, were reviewed. Data collected included preoperative disease activity, duration, host vascularity, pre- and postoperative vision, and antiviral use. Particular attention was given to all episodes of HSV recurrence, graft rejection, and failure.
Fifty-six patients (80%) were treated with prophylactic oral acyclovir after surgery. This cohort experienced fewer episodes of rejection (P = 0.006) and better overall graft survival (P = 0.04) than those who were not treated with prophylactic oral antivirals. There was no statistically significant difference in recurrence-free survival between the 2 groups (P = 0.22). Cox regression analysis failed to identify any single variable as a statistically significant predictor of recurrence, rejection, or graft failure.
Prophylactic oral acyclovir use after PK for HSV keratitis is associated with decreased episodes of rejection and improved graft survival.
确定穿透性角膜移植术(PK)治疗单纯疱疹病毒性(HSV)角膜炎后常规预防性口服阿昔洛韦对复发率、排斥反应和移植失败率的影响。
回顾了1990年8月1日至2000年12月31日期间在W.K.凯洛格眼科中心连续70例行PK治疗HSV角膜炎患者的记录。收集的数据包括术前疾病活动度、病程、宿主血管化程度、术前和术后视力以及抗病毒药物使用情况。特别关注HSV复发、移植排斥和失败的所有病例。
56例患者(80%)术后接受了预防性口服阿昔洛韦治疗。与未接受预防性口服抗病毒药物治疗的患者相比,该队列经历的排斥反应病例较少(P = 0.006),总体移植存活率更高(P = 0.04)。两组之间无复发生存率的统计学显著差异(P = 0.22)。Cox回归分析未能确定任何单一变量为复发、排斥或移植失败的统计学显著预测因素。
PK治疗HSV角膜炎后预防性口服阿昔洛韦与排斥反应病例减少和移植存活率提高相关。